Hemispherx Biopharma Inc

Receive alerts
Market Cap:
$4.12 m
52 weeks high
52 weeks low

Viewing results 1-25 of 38


Hemispherx Biopharma makes steady progress in cancer clinical trials

CEO Thomas K Equels said results from ongoing clinical trials over the next 18 months will act as ‘strong value drivers’ for the stock ...

3 days, 19 hours ago

Hemispherx reports positive survival data linked to stage 4 ovarian cancer using Ampligen as a combination therapy

Based on the Phase 1 study results, the company said that a new Phase 2 recurrent ovarian cancer clinical study has already begun at the University of Pittsburgh Medical Center...

1 week, 4 days ago

Hemispherx Biopharma corrects reports that mistakenly inflated the value of its private placement

The algorithm-generated reports stated that the company agreed to a $70 million equity distribution, when the actual amount was $4.5 million...

2 weeks, 3 days ago

Hemispherx Biopharma’s Ampligen treatment aims to disrupt the cancer market

CEO Tom Equels says Ampligen on a standalone basis has demonstrated effects in 'a number of solid tumors'...

on 07/05/2019

Hemispherx Biopharma CFO Adam Pascale to retire

CEO Thomas K Equels says his CFO leaves on a ‘well-deserved long vacation in September’ and upon his return will serve in a consulting capacity...

on 06/28/2019

Hemispherx Biopharma issues updates for ongoing immunotherapy trials of its drug Ampligen

Ampligen, approved in Argentina to treat Chronic Fatigue Syndrome, is involved in a pair of Phase 2 trials for recurrent ovarian cancer and prostate cancer...

on 06/17/2019

Hemispherx Biopharma initiated with a Buy rating and $8 price target at Maxim

Analyst Jason McCarthy says that with a $10M valuation and potentially positive data expected over 2019 and 2020, there’s plenty of upside...

on 06/14/2019

Hemispherx treats first patient with cancer drug Ampligen in Phase 2 clinical trials

The study looks at the effectiveness of ampligen in combination with the drug pembrolizumab at treating ovarian cancer...

on 06/12/2019

Hemispherx Biopharma shares soar as reverse split takes effect

The biopharma is looking to strengthen its position as it moves forward with several studies of its flagship drug, ampligen...

on 06/11/2019

Hemispherx Biopharma board approves 1-for-44 reverse stock split

Biotech hopes split will achieve a value of about $5 per share -- making the stock more attractive to Wall Street investors ...

on 05/31/2019

Hemispherx Biopharma’s well-funded to take promising cancer drug Ampligen through clinical trials

CEO Thomas K Equels says it’s time for the company to seek out big pharma partners who share its 'excitement and enthusiasm' for Ampligen’s potential...

on 05/16/2019

Hemispherx Biopharma says FDA authorizes study using aspirin and flagship drug ampligen to treat prostate cancer

The Phase 2 study will be carried out at the Roswell Park Comprehensive Cancer Center in Buffalo and involve up to 60 patients...

on 05/13/2019

Hemispherx sees potential commercialization of flagship drug ampligen for Chronic Fatigue Syndrome

The company said results of a recent Stanford University diagnostic test of 20 patients with MF/CFS were 'impressive'...

on 05/06/2019

Hemispherx Biopharma's stock soars on 'significant progress' in ovarian cancer study of Ampligen

The ovarian cancer study is being conducted at the University of Pittsburgh Medical Center...

on 04/30/2019

Hemispherx Biopharma promotes Ellen Lintal to chief accountant post

Lintal joined the Florida biopharmaceutical group in 2018 as a vice-president of finance & control...

on 04/22/2019

Hemispherx Biopharma kicks off Phase 1 trial to treat advanced breast cancer with key drug Ampligen

The first participant in the study at Roswell Park Comprehensive Cancer Center received initial dosing this week ...

on 04/02/2019

Hemispherx Biopharma makes headway in advancing flagship cancer drug Ampligen in 2018

Ampligen is being studied to treat nine types of cancer: renal cell carcinoma, melanoma, non-small cell lung cancer, ovarian, breast, colorectal, urothelial, prostate and pancreatic cancer...

on 04/02/2019

Hemispherx rises as five trials for cancer drug Ampligen kick off this year

The biopharma is focusing on the use of Ampligen as a cancer immuno-therapy...

on 03/13/2019

Hemispherx Biopharma takes cancer war to new stage with drug Ampligen

A series of trials underway at major cancer research hospitals are evaluating the company's flagship cancer drug Ampligen...

on 03/08/2019

Hemispherx Biopharma expects gross proceeds of $5.3M from rights offering

Closing of the transaction is expected on or about Friday March 8...

on 03/06/2019